Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Subfertility treatments
- Ovulation induction
- Clomiphene citrate (CC)
- Mechanism of clomiphene citrate (CC)
- CC :biological effects
- CC: indications, dosage and cycle monitoring
- CC: cycle management
- CC: number of cycles
- CC: results
- CC: complications & side effects
- CC: side effects
- Clomiphene citrate
- Clomiphene + IUI
- Gonadotropins ± IUI
- FSH vs. CC in IUI for unexplained subfertility
- Unexplained infertility: ‘‘do something to help.’’
- Gonadotropins ± IUI
- Gonadotropins: hMG- Pergonal
- Gonadotropins: a new era
- HMG preparation
- Gonadotropins: hMG
- HMG: mechanism and cycle monitoring
- Multiple follicles due to ovarian hyperstimulation
- HMG: dosage
- HMG: induction of ovulation
- HMG: results
- FSH/hMG: complications
- As demand increased, quality decreased
- Purification of FSH
- Evolution of FSH/hMG
- Recombinant FSH
- Expression of hFSH in CHO cells
- Gonadotropins: from hMG to rFSH
- The advantages of GNr over urinary products
- Luteal phase dysfunction
- Luteal phase deficiency (LPD) (1)
- Luteal phase deficiency (LPD) (2)
- Luteal phase deficiency (LPD) (3)
- Luteal phase deficiency (LPD) (4)
- Role of GnRHa, hCG, progesterone, and E2
- Luteal phase deficiency (LPD) (5)
- LPD: progestatives luteal support
- Luteal progesterone support (LPD)
- Midluteal GnRHa
- Tubal damage (1)
- Tubal damage (2)
- Tubal damage (3)
- Tubal damage (4)
- HSG: the optimal contrast medium?
- Tubal damage: diagnosis
- Tubal damage: treatment
- Obesity (1)
- Obesity associated with
- Obesity (2)
- Morbid obesity causes:
- Obesity and conception and implantation
- The reproductive-endocrine effects of adipokines
- The adverse effects of obesity on IVF/ART (1)
- The adverse effects of obesity on IVF/ART (2)
- The prevalence of metabolic syndrome in PCOS
- The obesity-PCOS association
- The adverse effects of obesity
- Male obesity
- Male obesity: effects
- POF / POI (1)
- POF / POI (2)
- POF / POI (3)
- Genetics of POI: developments & opportunities
- POF / POI (4)
- Genetic etiology of POF/POI
- Autoimmune endocrinopathies & POF/POI
- Autoimmune etiology: POF/POI
- POF / POI (5)
- Primary ovarian insufficiency
- POF/POI: summary
- Thank you
Topics Covered
- Disorders of ovulation: diagnosis and treatment protocols
- Development of gonadotropic hormone preparations
- Corpus luteum insufficiency
- Tubal damage
- Obesity: perturbation of the hormonal profile, possible direct effect on the oocyte
- Premature ovarian failure (POF/POI)
- Genetic background of infertility
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Blumenfeld, Z. (2019, July 31). Subfertility treatments [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 24, 2024, from https://doi.org/10.69645/QYWO3315.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Zeev Blumenfeld has no commercial/financial relationships to disclose
Other Talks in the Series: The Female Reproductive System: from Basic Science to Fertility Treatments
Transcript
Please wait while the transcript is being prepared...
0:00
I am Zeev Blumenfeld,
Associate Professor for reproductive endocrinology,
and OBGYN at the Technion Faculty of Medicine in Haifa, Israel.
I've been invited to talk in the series of
female reproductive system of subfertility treatment.
0:22
The issues I'll be talking about are disorders of ovulation,
diagnosis and treatment protocols,
mainly addressing clomiphene citrate and gonadotropins.
Development of gonadotropins hormone preparation,
from urine extraction, to recombinant synthesis.
Corpus luteum insufficiency, also called luteal phase defect.
Tubal damage, obesity, perturbation of the hormonal profile,
possibly direct effect on the oocyte.
Premature ovarian failure, also called premature ovarian insufficiency,
and genetic background of infertility.
1:04
Next slide, we'll start with ovulation induction by clomiphene citrate and gonadotropins.
Clomiphene citrate has several commercial branch,
1:14
Clomid, Serophene, Ikaclomin in Israel.
It is a non-steroidal estradial agonists-antagonists molecule,
a selective estrogen receptor modulator similar to tamoxifen or raloxifene.
Clomiphene citrate is a racemic mixture of two stereo-chemical isomers,
zuclomifene and enclomifene, as we can see on the upper right-side of this slide.
In the next slide,
we see the structural similarity of clomiphene citrate to estradial,